Amoxicillin/Clavulanic Acid Safety During Breastfeeding

Safety Profile in Breastfeeding

Amoxicillin/clavulanic acid is classified as compatible with breastfeeding according to both FDA (Category B) and clinical practice guidelines, with a strength of evidence supporting its safety 1, 2
The American Academy of Dermatology suggests using oral amoxicillin/clavulanic acid in breastfeeding patients who require systemic antibiotics, based on high-quality evidence 3, 4, 5

Amoxicillin/clavulanic acid is preferred over doxycycline, which should be limited to 3 weeks without repeating courses if no suitable alternative is available, due to its safer profile for breastfeeding infants 3, 4
Amoxicillin/clavulanic acid is preferred over clindamycin, which may increase risk of GI side effects in the infant, according to clinical guidelines 3, 4

Most systemic antibiotics, including amoxicillin/clavulanic acid, will be present in breast milk to some degree, which could potentially cause falsely negative cultures if the breastfed infant develops a fever requiring evaluation, with moderate evidence supporting this concern 1, 2
Amoxicillin/clavulanic acid may produce mild gastrointestinal effects due to alteration of intestinal flora in breastfed infants, based on moderate-quality evidence 1, 2

To minimize infant exposure, consider using the lowest effective dose for the shortest duration needed, as recommended by clinical guidelines 6

The American Academy of Dermatology recommends amoxicillin/clavulanic acid as a safe option during breastfeeding, supported by high-quality evidence from multiple clinical practice guidelines, including those from major medical societies 7

Changes in stool pattern or consistency in breastfed infants should be monitored, as recommended by guidelines from the American Academy of Dermatology 7
The lowest effective dose of amoxicillin/clavulanic acid should be used for the shortest necessary duration to minimize infant exposure while maintaining therapeutic efficacy, as suggested by the American Academy of Dermatology 7

Amoxicillin/clavulanic acid has a more established safety profile than newer agents with limited lactation data, making it a preferred choice over alternatives, according to the American Academy of Dermatology 7